Biomarin Pharmaceutical Inc Revenue Growth Rates (BMRN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Biomarin Pharmaceutical Inc  (NASDAQ: BMRN)
 

BMRN's Revenue Growth by Quarter and Year

Biomarin Pharmaceutical Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BMRN/growth
https://api.csimarket.com/api/v1/companies/BMRN/fundamentals
https://api.csimarket.com/api/v1/companies/BMRN/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
BMRN Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 1,024.65
2nd Quarter June 989.71
1st Quarter March 766.21
FY 2,780.57

BMRNs Annual Revenue
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2025 $ 3,221.25 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2024 $ 2,853.92 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2023 $ 2,419.23 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2022 $ 2,096.04 millions
Biomarin Pharmaceutical Inc's Revenue in the fiscal year 2021 $ 1,846.28 millions




BMRN Revenue third quarter 2026 Y/Y Growth Comment
Biomarin Pharmaceutical Inc achieved in the third quarter 2026, above Company average Revenue growth of 32.02% year on year, to $ 1,024.65 millions.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 85 other companies have achieved higher Revenue growth. While Biomarin Pharmaceutical Inc' s Revenue rise of 32.02% ranks overall at the positon no. 1064 in the third quarter 2026.


BMRN Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 32.02 %
2nd Quarter June 19.91 %
1st Quarter March 2.83 %
FY   -

Financial Statements
Biomarin Pharmaceutical Inc's third quarter 2026 Revenue $ 1,024.65 millions BMRN's Income Statement
Biomarin Pharmaceutical Inc's third quarter 2025 Revenue $ 776.13 millions Quarterly BMRN's Income Statement


BMRN Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 3.53 %
2nd Quarter June 29.17 %
1st Quarter March -12.39 %
FY (Year on Year)   -


Back to BMRN Growth rate Comparisons >> Back to BMRN Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #211
Overall #1064

Revenue Y/Y Growth Statistics
High Average Low
57.18 % 15.03 % -36.91 %
(Mar 31 2015)   (Mar 31 2011)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #86
Healthcare Sector #211
Overall #1064
Revenue Y/Y Growth Statistics
High Average Low
57.18 % 15.03 % -36.91 %
(Mar 31 2015)   (Mar 31 2011)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Biomarin Pharmaceutical Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
99.32 % 4.87 % -47.25 %
(Dec 31 2009)  


BMRN's III. Quarter Q/Q Revenue Comment
Biomarin Pharmaceutical Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.53% quarter on quarter, to $ 1,024.65 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the -5.97% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Biomarin Pharmaceutical Inc's Revenue growth quarter on quarter, overall rank is 379.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #379
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #379
Revenue Q/Q Growth Statistics
High Average Low
99.32 % 4.87 % -47.25 %
(Dec 31 2009)  


BMRN's III. Quarter Q/Q Revenue Comment
Biomarin Pharmaceutical Inc achieved in the III. Quarter 2026 below company average Revenue growth of 3.53% quarter on quarter, to $ 1,024.65 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -5.97% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Biomarin Pharmaceutical Inc's Revenue growth quarter on quarter, overall rank is 379.


Biomarin Pharmaceutical Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 3,655.13
Y / Y Revenue Growth (TTM) 18.14 %
Year on Year Revenue Growth Overall Ranking # 922
Seqeuential Revenue Change (TTM) 7.3 %
Seq. Revenue Growth (TTM) Overall Ranking # 2196


Cumulative Revenue growth Comment
Biomarin Pharmaceutical Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.14% year on year, to $ 3,655 millions if the fiscal year would have ended in Sep 30 2026.
Biomarin Pharmaceutical Inc's trailing twelve months Revenue growth was higher than company's average 14.62% and higher than 11.2% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 7.3 % from $3406.61 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at14.62%.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 784 to 922.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 182
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
40.31 %
 14.62 %
-2.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 2196
Cumulative Revenue growth Comment
Biomarin Pharmaceutical Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 18.14% year on year, to $ 3,655 millions if the fiscal year would have ended in Sep 30 2026.
Biomarin Pharmaceutical Inc's trailing twelve months Revenue growth was higher than company's average 14.62% and higher than 11.2% growth in Jun 30 2026.
But from twelve months ended Jun 30 2026 rise was beneth at 7.3 % from $3406.61 millions achieved in the period from Jun 30 2026 to Sep 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at14.62%.
The momentum is even more impressive from twelve months ended Jun 30 2026 exhibited at 7.3 % increase from $3406.61 millions in the period from Jun 30 2026 to Sep 30 2025.

In the Healthcare sector 181 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 784 to 922.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 105
Healthcare Sector # 182
Overall # 922

Revenue TTM Y/Y Growth Statistics
High Average Low
40.31 %
14.62 %
-2.16 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 105
Sector # 325
S&P 500 # 2196




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
BMRN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue growth for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions
Strata Critical Medical Inc 50.27%$ 50.272 millions
Madrigal Pharmaceuticals Inc 50.13%$ 50.127 millions
Immucell Corporation49.91%$ 49.912 millions
Hims and Hers Health Inc 48.88%$ 48.877 millions
Maxcyte inc 48.66%$ 48.660 millions
Billiontoone Inc 47.43%$ 47.431 millions
Arcutis Biotherapeutics Inc 45.05%$ 45.052 millions
Zevra Therapeutics Inc 44.86%$ 44.864 millions
Xeris Biopharma Holdings Inc 44.16%$ 44.158 millions
Nephros Inc 43.60%$ 43.602 millions
Cardiff Oncology Inc 42.50%$ 42.500 millions
Neurocrine Biosciences Inc 41.24%$ 41.238 millions
Transmedics Group Inc 41.15%$ 41.149 millions
Uniqure N v 40.39%$ 40.394 millions
Harrow Inc 40.00%$ 40.001 millions
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions


About Biomarin Pharmaceutical Inc Revenue Growth Rates (BMRN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Biomarin Pharmaceutical Inc (CIK 1048477).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001048477-26-000023
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Biomarin Pharmaceutical Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.